Dual CAR-T cell therapy - ImmPACT Bio
Alternative Names: iCAR Targeting T-cell therapy; iCAR-T cell therapyLatest Information Update: 10 Jul 2023
At a glance
- Originator ImmPACT Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 10 Jul 2023 Discontinued - Preclinical for Lung cancer in USA (Parenteral) (ImmPACT Bio pipeline, July 2023)
- 21 Nov 2022 Preclinical trials in Lung cancer in USA (Parenteral) (ImmPACT Bio pipeline, November 2022)